Image: Streptacidiphilus sp.
February 15, 2018- NovoBiotic Pharmaceuticals, LLC is awarded a 3-year, $3MM SBIR Phase II NIH NIAID grant “Preclinical development of teixobactin, a new antibiotic". This grant is to support the continuing development of teixobactin as a novel agent to treat drug-resistant bacterial infections such as MRSA and VRE.
“Since our discovery of teixobactin, we have made great strides in understanding and improving the compound’s properties. We are extremely pleased with this award, which will help accelerate teixobactin through formal preclinical studies to the clinic.” -Dallas Hughes, President, NovoBiotic Pharmaceuticals, LLC
January 19, 2018- NovoBiotic Pharmaceuticals, LLC is awarded a SBIR Phase I NIH NIAID grant “Preclinical Development of Novo29, a New Antibiotic". This grant is to support the early development of Novo29 as a novel agent to treat serious bacterial infections such as MRSA and VRE.
“Novo29 is yet another new lead compound mined from our unique collection of 64,000+ previously unculturable microbes. We are very pleased that NIH has recognized the potential of Novo29 as an attractive new antibiotic class to combat the escalating problem of antibiotic resistance.” -Losee Ling, VP of Research and Development, NovoBiotic Pharmaceuticals, LLC
August 9, 2017 – NovoBiotic Pharmaceuticals, LLC is awarded a two-year, $600K SBIR Phase I NIH NIAID grant "Novel Antibiotics from Marine Invertebrate Microbes". This grant will support the cultivation of novel marine microorganisms using Novobiotic’s proprietary iChip technology. The selection of antimicrobials they produce will set the stage for developing new antibiotics.
“The rise of multi-drug resistant pathogens is a major public health concern, but the rate of antibiotic discovery is in steady decline. This award will help us identify a promising source of chemical novelty, microbes associated with marine invertebrates. We will use our innovative platform to grow such microorganisms, and develop the antimicrobial compounds they produce. These advances address the urgency of combating antimicrobial resistance."— Amy L. Spoering, Director of Biological Research, NovoBiotic Pharmaceuticals, LLC.
August 4, 2017 – NovoBiotic Pharmaceuticals, LLC is featured in an in depth PBS Newshour series with economics correspondent Paul Solman and science correspondent Miles O’Brien on the financial barrier stopping new antibiotics. As current antibiotics begin to lose their punch, there’s an economic reality putting a damper on development. NovoBiotic Pharmaceuticals is featured as a company overcoming barriers using their patented technology with an emphasis on their lead compound teixobactin.
November 21, 2016 – NovoBiotic Pharmaceuticals, LLC is awarded a grant from the Bill & Melinda Gates Foundation entitled "Development of orally active analogues of teixobactin."
“This project is a consortium of five leading laboratories in the US and UK with the aim of producing an orally active version of teixobactin, a promising new antibiotic for treating tuberculosis (TB) and other bacterial infections. An orally active drug is particularly important for treating TB in impoverished countries, where consistent access to injectable drugs over a long treatment period can be difficult "— Dallas E. Hughes, President, NovoBiotic Pharmaceuticals, LLC.
September 16, 2016 – NovoBiotic Pharmaceuticals, LLC is awarded a one year funded extension from the Bill & Melinda Gates Foundation on their grant entitled "Identification of new anti-tuberculosis drugs from formerly ‘unculturable’ soil microbes."
“This award builds on our early promising results to find new antibiotics to combat tuberculosis using our unique drug discovery platform "— Dallas E. Hughes, President, NovoBiotic Pharmaceuticals, LLC
July 15, 2016 – NovoBiotic Pharmaceuticals, LLC will receive $2.5M over a five year period as part of a multi-center grant from the National Institutes of Health’s National Institute of Allergy and Infectious Disease (NIH NIAID) awarded to Kim Lewis at Northeastern University. The funds from this grant, entitled “Resolving the Bottleneck in Antibiotic Discovery”, will be used to develop and implement a new platform that will facilitate quick identification of new antibiotics from natural sources.
“We are excited to be involved in this breakthrough research that has the potential to eliminate one of the most troublesome bottlenecks in natural product discovery: spending resources on chasing known or uninteresting compounds.” – Amy Spoering, Director of Biological Research.
July 13, 2016 — NovoBiotic Pharmaceuticals, LLC is awarded a two-year, $1.48M SBIR Phase II NIH NIAID grant "Exploratory Chemistry on a New Antibiotic". This grant will be used to help advance NovoBiotic’s teixobactin program for treatment of serious drug-resistant infections such as MRSA and vancomycin-resistant enterococci (VRE).
“New classes of antibiotics like teixobactin are desperately needed due to the spread of drug resistance, and this grant will enable us to produce new, optimized versions of teixobactin for advancement to the clinic” – Aaron J. Peoples, Director of Chemistry.
October 27, 2015 — NovoBiotic Pharmaceuticals, LLC is awarded a grant from the Bill & Melinda Gates Foundation entitled "Evaluation of teixobactin and lassomycin as TB therapeutics".
“We are excited to advance our two highly promising antibiotics towards treating tuberculosis (TB). TB is second only to HIV/AIDS as the biggest killer worldwide due to a single infectious agent, and is particularly devastating in low- and middle-income countries. In this grant we are pleased to be working with some of the leading scientific groups in the country to progress these compounds towards the clinic”. — Dallas E. Hughes, President, NovoBiotic Pharmaceuticals, LLC.
August 25, 2015 — NovoBiotic Pharmaceuticals, LLC is awarded a grant from the Bill & Melinda Gates Foundation entitled "Identification of new anti-tuberculosis drugs from formerly ‘unculturable’ soil microbes."
“This award allows us to expand our natural product screening platform to identify new antibiotics with specific activity against the tuberculosis bacteria, which increases the likelihood of treating the disease while leaving the beneficial gut microbiome intact."— Dallas E. Hughes, President, NovoBiotic Pharmaceuticals, LLC.
June 15, 2015 — NovoBiotic Pharmaceuticals, LLC is awarded an NIH NIAID SBIR grant entitled "Microbial symbionts of marine invertebrates for antibiotic discovery".
“This award allows us to apply our drug discovery platform to virtually unexplored territories. It is known that many unique active molecules are found in marine invertebrates and it is suspected they are produced by the organism's microbiome. We are excited to be using our technology to cultivate these microbes to discover new therapeutics."— Amy Spoering, Director of Biological Research, NovoBiotic Pharmaceuticals, LLC.
February 2, 2015 — NovoBiotic Pharmaceuticals, LLC reports that their recent Nature paper describing the discovery and development of their new antibiotic teixobactin (Ling et. al. 2015), has become the highest impact paper of over 60,000 articles tracked by Nature of a similar age http://www.nature.com/nature/journal/v517/n7535/nature14098/metrics.
“We are very pleased with the enthusiastic response towards our manuscript. Clearly, the discovery of teixobactin confirms the vast potential that natural products can still provide towards finding new therapeutics. With NovoBiotic’s unique culturing technologies to isolate previously unculturable microbes, we are perfectly positioned to unleash this potential"— Losee Ling, VP of Research and Development, NovoBiotic Pharmaceuticals, LLC.
January 28, 2015 — NovoBiotic Pharmaceuticals, LLC is awarded two NIH NIAID SBIR grants. A Phase II grant is for “Preclinical Development of Teixobactin, a New Antibiotic”, and a Phase I grant is for “Specific Anti-TB compounds from Uncultured Bacteria".
“The discovery of teixobactin, a new class of antibiotic that minimizes the chance of resistance, further underscores the promise of NovoBiotic’s culturing technologies for accessing new natural product chemistry. The Phase II grant will help support advancement of teixobactin to the clinic. The Phase I grant aims at using our technologies to discover anti-tuberculosis specific compounds, which are desperately needed to combat this worldwide scourge” — Dallas Hughes, President, NovoBiotic Pharmaceuticals, LLC.
January 7, 2015 — NovoBiotic Pharmaceuticals, LLC reports the discovery of teixobactin, a new antibiotic without detectable resistance, published in Nature.
NovoBiotic Pharmaceuticals, LLC announces the discovery and preclinical development of teixobactin, a compound belonging to a new class of antibiotics. As reported in the journal Nature (Ling et. al. 2015), the compound shows potent killing against a broad panel of bacterial pathogens including methicillin resistant Staphylococcus aureus (MRSA) and vancomycin resistant enterococci (VRE). (Press release).
Older press releases here.
NovoBiotic is a drug discovery company harnessing "unculturable" microorganisms to develop new therapeutics.
For more information on NovoBiotic contact:
NovoBiotic Pharmaceuticals, LLC
767C Concord Avenue
Cambridge, MA 02138
ph: 1-617-864-2880 x105